Advertisement
UK markets close in 8 hours 12 minutes

  • FTSE 100

    8,126.58
    +47.72 (+0.59%)
     

  • FTSE 250

    19,663.79
    +61.81 (+0.32%)
     

  • AIM

    754.07
    +0.95 (+0.13%)
     

  • GBP/EUR

    1.1650
    -0.0006 (-0.05%)
     

  • GBP/USD

    1.2501
    -0.0010 (-0.08%)
     

  • Bitcoin GBP

    51,447.64
    -21.63 (-0.04%)
     

  • CMC Crypto 200

    1,389.25
    -7.29 (-0.52%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CRUDE OIL

    84.10
    +0.53 (+0.63%)
     

  • GOLD FUTURES

    2,350.20
    +7.70 (+0.33%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,670.86
    +386.32 (+2.24%)
     

  • DAX

    18,021.41
    +104.13 (+0.58%)
     

  • CAC 40

    8,067.40
    +50.75 (+0.63%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

BUZZ-GlaxoSmithKline: UBS downgrade, stock going ex-div hit shares

Reuters - UK Focus

** Drugmaker GlaxoSmithKline down 3 percent, hit by trading ex-dividend and downgrade to "neutral" from "buy" by brokerage UBS (NYSEArca: FBGX - news)

** UBS analyst Alexandra Hauber says GSK's 2020 pharma outlook implies a sharp deterioration of pharma profit margin, excluding the HIV business ViiV, with ViiV blockbuster profits appearing to cross-subsidise low profits elsewhere

** Britain's biggest pharmaceuticals group set out its strategy and long-term goals last week, following a re-shaping of the group after $20 billion-plus asset swap with Novartis (RM (LSE: RM.L - news) : ben.hirschler.thomsonreuters.com@reuters.net)